CardioBrief: At Last, a Positive Diabetes Drug Outcomes Trial?

(MedPage Today) -- Study of SGLT2 inhibitor empagliflozin may be the first to show cardiovascular benefit
Source: MedPage Today Neurology - Category: Neurology Source Type: news